Integra LifeSciences

What Integra LifeSciences does

Integra LifeSciences Holdings Corporation (NASDAQ: IART) is a Princeton, New Jersey-based global medical technology company founded in 1989 that develops, manufactures, and sells medical devices and regenerative tissue products for neurosurgery, wound reconstruction, ENT, plastic and reconstructive surgery, and general surgical instrumentation. Its product architecture rests on six integrated platforms: (1) Neurosurgery and tissue ablation (CUSA Clarity ultrasonic aspirator, dural repair, cranial reconstruction and stabilization, Aurora minimally invasive surgery); (2) Neurocritical care and hydrocephalus management (external CSF drainage, fixed/flow-regulating/programmable valves, catheters); (3) Wound reconstruction (Integra Dermal Matrices, PriMatrix Dermal Scaffold, MicroMatrix UBM and Cytal, AmnioExcel, MediHoney); (4) Soft tissue solutions (nerve and tendon, hernia repair, plastic and reconstructive); (5) Surgical instrumentation and lighting under brands such as Jarit, MicroFrance, Miltex, Padgett, Omni-Tract, Ruggles-Redmond, and Integra DUO/MLX/Luxtec lighting; and (6) ENT (TruDi AI-powered navigation, balloon sinuplasty, airway/nasal/eustachian dilation) acquired via the $275M Acclarent purchase in April 2024.

Underlying technology is anchored in proprietary collagen biomaterials (Ultra Pure Collagen from bovine deep flexor tendon) with demonstrated safety in over 10 million implants, plus tissue ablation, programmable valve, and AI-assisted surgical navigation platforms. The company generates revenue primarily through direct sales of capital equipment and consumables to hospital systems, ambulatory surgery centers, and physician practices via a global field sales organization led by a Chief Commercial Officer, with manufacturing across 24 plants in the U.S., Puerto Rico, Mexico, Europe, and China.

In FY2025, Integra reported $1,635.2 million in revenue (up 1.5% reported, down 0.7% organically), with Q1 2026 revenue of $392 million (+2.4% reported) and FY2026 guidance of $1,662–$1,702 million. The company employs 4,200+ people globally and is led by Stuart M. Essig, who returned as President and CEO in May 2026 after previously serving as CEO from 1997 to 2012. Material recent developments include the Acclarent acquisition (ENT platform), a new CCO and CTO, FDA 510(k) clearance for CUSA Clarity in cardiac surgery, ongoing TruDi navigation AI safety concerns and litigation, and a MediHoney wound and burn product recall that triggered 65 Princeton job cuts.

Name

Integra LifeSciences

Legal name

Integra LifeSciences Holdings Corporation

Website

https://integralife.com

Company type

Public

Founded year

1989

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Integra LifeSciences (NASDAQ: IART) is a global medical device company that develops and sells surgical implants, regenerative collagen products, ultrasonic tissue ablation systems, and AI-assisted ENT navigation tools to hospital systems, ambulatory surgery centers, and physician practices across neurosurgery, wound reconstruction, ENT, and surgical instrumentation.

Ownership category

akta.pro rank

Product category

Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS) (HLAHADAA)

akta.pro secondary industries

Surgical Navigation, Tracking & Intraoperative Guidance (Ortho/Neuro/ENT) (HLAHADAG), Single-Use Surgical Devices & Procedure Packs (Disposable instruments, drapes, kits) (HLAHADAM), Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools) (HLAHADAN)

Keywords

• Neurosurgical devices
• Tissue reconstruction products
• Wound care solutions
• ENT surgical instruments
• Regenerative collagen biomaterials

Headquarters

HQ city

Princeton

HQ country

United States

HQ region

North America

Offices11 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Medical Device and Product Sales: Sales of surgical instruments, implants, wound care products, and capital equipment to hospitals and healthcare providers. Revenue includes both one-time product sales and recurring consumables.
2. Product Portfolio Revenue: Full-year 2025 revenues of $1,635.2 million, with Q4 2025 revenues of $434.9 million and Q1 2026 revenues of $392 million

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Integra LifeSciences designs, manufactures, and sells medical devices and regenerative tissue technologies used in neurosurgery, wound reconstruction, ENT surgery, and general surgical procedures. Its portfolio spans capital equipment (e.g., CUSA tissue ablation systems), implants and consumables (dural repair, hydrocephalus valves, cranial stabilization), engineered collagen and amniotic wound matrices, surgical instruments, surgical lighting, and ENT balloon and navigation systems, sold to hospitals, ambulatory surgery centers, and physician practices worldwide.

Product overview

Integra LifeSciences is a global medical technology company offering a diversified portfolio of highly differentiated products and solutions across neurosurgery and tissue reconstruction. The company's product architecture consists of multiple integrated platforms: (1) Neurosurgery/Tissue Ablation (CUSA Clarity, Dural Repair, Cranial Reconstruction, Cranial Stabilization, Minimally Invasive Surgery with Aurora Surgiscope), (2) Neurocritical Care/Hydrocephalus Management (External CSF Drainage, Fixed/Programmable/Flow Regulating Valves, Catheters), (3) Wound Reconstruction and Care (Integra Dermal Matrices, PriMatrix Dermal Scaffold, MicroMatrix UBM/Cytal Wound Matrix, AmnioExcel Allografts, MediHoney Dressings, Total Contact Casting), (4) Soft Tissue Solutions (Nerve & Tendon, Hernia Repair, Plastic Reconstructive Surgery), (5) Surgical Instrumentation and Lighting (Surgical Instruments under multiple brands including Jarit, MicroFrance, Miltex; Surgical Lighting including Integra DUO LED, Luxtec), and (6) Ear, Nose and Throat (ENT) portfolio acquired through Acclarent including TruDi Navigation System with AI capabilities, Balloon Sinuplasty, Airway/Nasal Dilation Systems, and Eustachian Tube Balloon Dilation. The company operates across 24 global manufacturing plants and serves healthcare professionals in multiple surgical specialties.

Differentiator

Problem solved

Functional benefit

Brands

• Codman Specialty Surgical: Neurosurgery and neuro-critical care products including dural repair, CSF management, cranial stabilization and fixation
• Acclarent
• Tissue Technologies
• CUSA
• Aurora
• Integra ENT
• Jarit
• MicroFrance
• Miltex

Products and services

• CUSA Clarity Ultrasonic Surgical Aspirator System Capital equipment system for ultrasonic surgical tissue ablation in neurosurgery, orthopedic, liver, and cardiac procedures, including the CUSA Clarity model cleared for cardiac use in November 2025.
• Dural Repair Products Dural substitutes and repair materials used by neurosurgeons to close the dura mater following cranial and spinal procedures.
• Cranial Reconstruction Implants
• Cranial Stabilization and Fixation Devices
• Aurora Minimally Invasive Surgery System
• Neuro ICU / External CSF Drainage Products
• Hydrocephalus Management Products
• Integra Dermal Matrices
• PriMatrix Dermal Scaffold Fetal bovine dermis dermal scaffold for wound reconstruction in partial and full-thickness wounds, pressure ulcers, diabetic ulcers, venous ulcers, and surgical wounds.
• MicroMatrix UBM and Cytal Wound Matrix Urinary bladder matrix (UBM) particulate and sheet products, including MicroMatrix Flex and Cytal Wound Matrix, for complex wound management.
• AmnioExcel Amniotic and Placental Allograft Membranes
• MediHoney Wound and Burn Dressing
• Nerve and Tendon Repair Products
• Hernia Repair and Abdominal Wall Products
• Plastic and Reconstructive Surgery Products
• Surgical Instruments (Integra, Jarit, MicroFrance, Omni-Tract, Ruggles-Redmond, Padgett, Miltex)
• Surgical Lighting Systems
• TruDi Navigation System
• Balloon Sinuplasty Products
• Airway Dilation System
• Nasal Dilation System
• Eustachian Tube Balloon Dilation System

Quantifiable outcome

• Fetal bovine dermis-based PriMatrix supported vascularized tissue formation prior to definitive closure, accelerating patient recovery timeline
• +1 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

Three partnerships are on record, tiered supporting, core and minor.

• Morgan LewissupportingImplementation/ SI/ Consulting Partner · 13 December 2023Morgan Lewis law firm represented Integra LifeSciences in the acquisition of Acclarent from Johnson & Johnson
• Ethicon, Inc. (Johnson & Johnson)coreStrategic or Co-development Partner · 13 December 2023Acclarent, Inc. was acquired from Ethicon, Inc., expanding Integra's presence in the ENT device segment with innovative balloon technologies and surgical systems
• Companies Seeking Collagen PartnershipsminorOthersIntegra offers collagen biomaterial expertise for companies seeking strategic alliances including private label partnerships, material supply, and customer-specific product development

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Medtronic: Medtronic is the global leader in neurosurgery, ENT (via Mazor and cranial therapies), and surgical instruments with significantly broader scale. Directly comparable to Integra's Codman, CUSA, TruDi, and Acclarent franchises and competes for the same neurosurgery and ENT hospital budgets.
• Stryker: Stryker operates a large surgical instruments, neurosurgery, and ENT business (acquired Wright Medical, Entellus) competing directly against Integra's surgical instrument, cranial fixation, and balloon sinuplasty portfolios. Comparable in serving the same surgical suite customers with hospital-wide contracts.
• Conmed: Conmed is a mid-cap surgical and ENT device company with a comparable product mix spanning ENT surgical instruments, electrosurgery, and general surgical devices. Closest peer by size, business model, and ENT focus, competing with both Integra's Acclarent franchise and Jarit/MicroFrance surgical instruments.
• Smith+Nephew: Smith+Nephew operates a significant advanced wound management business (Allevyn, PICO) competing directly with Integra's PriMatrix, MicroMatrix, and MediHoney portfolios. Also a direct competitor in surgical instruments and ENT, making it one of the most product-overlapping peers.

Broad incumbents

• Johnson & Johnson MedTech: J&J MedTech (Ethicon, DePuy Synthes) sold Codman Neurosurgery to Integra in 2017 and Acclarent to Integra in 2024, and remains a broad incumbent with overlapping ENT, surgical instruments, wound closure, and neurosurgery offerings. Highly comparable for competitive context even though Integra has divested product lines back to J&J over time.
• Baxter International: Baxter's Medical Products and Therapies segment overlaps with Integra's surgical and wound reconstruction businesses, particularly in hydrocephalus shunts (Baxter historically strong), dura repair, and advanced wound care. Comparable broad medtech peer with similar hospital channel.
• Becton Dickinson (BD): BD's BDX Medical segment produces surgical instruments, infection prevention, and biosurgery products overlapping with Integra's Miltex surgical instruments, Jarit, MicroFrance, and dural/sealant portfolio. Comparable as a hospital-channel surgical device incumbent.

Emerging players

• Organogenesis: Organogenesis is a smaller pure-play in advanced wound care and regenerative medicine (Apligraf, Dermagraft), competing head-to-head with Integra's PriMatrix, AmnioExcel, and Cytal wound matrices. Directly comparable technology platform and call point in wound care specialists.
• MiMedx: MiMedx is a smaller regenerative medicine company focused on amniotic membrane allografts (EpiFix, AmnioFix) and wound care, directly competing with Integra's AmnioExcel portfolio. Comparable technology and call point though significantly smaller scale.
• Coloplast: Coloplast's Wound & Skin Care division (Biatain, Conveen) competes with Integra's advanced wound care and skin substitute products, particularly in chronic wound management. Comparable wound care call point though Coloplast is stronger in ostomy and continence care.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/integra-lifesciences
• Xx.com/integra_life
• Facebookfacebook.com/127706797321882

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries3 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A22 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Integra LifeSciences